Nearly one‐fourth of the global population is infected by Mycobacterium tuberculosis (Mtb), and approximately 90%–95% remain asymptomatic as latent tuberculosis infection (LTBI), an estimated 5%–10% of those with latent infections will eventually progress to active tuberculosis (ATB). Although it is widely accepted that LTBI transitioning to ATB results from a disruption of host immune balance and a weakening of protective immune responses, the exact underlying immunological mechanisms that promote this conversion are not well characterized. Thus, it is difficult to accurately predict tuberculosis (TB) progression in advance, leaving the LTBI population as a significant threat to TB prevention and control. This article systematically explores three aspects related to the immunoregulatory mechanisms and translational research about LTBI: (1) the distinct immunocytological characteristics of LTBI and ATB, (2) LTBI diagnostic markers discovery related to host anti‐TB immunity and metabolic pathways, and (3) vaccine development focus on LTBI.This article is categorized under:
Infectious Diseases > Molecular and Cellular Physiology
Infectious Diseases > Genetics/Genomics/Epigenetics
Immune System Diseases > Genetics/Genomics/Epigenetics